Proteasome-dependent pharmacological rescue of cystic fibrosis transmembrane conductance regulator revealed by mutation of glycine 622

Journal of Pharmacology and Experimental Therapeutics

Volumn 325, Issue 1, 2008, Pages 89-99

  Norez, Caroline ^a   Bilan, Frédéric ^a   Kitzis, Alain ^a   Mettey, Yvette ^a   Becq, Frédéric ^a  

^a UNIVERSITÉ DE POITIERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; BENZO[F]QUINOXALINE DERIVATIVE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BREFELDIN A; CALNEXIN; CHLORIDE CHANNEL; GELDANAMYCIN; GLUCOSIDASE; GLYCINE; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; MIGLUSTAT; PHENANTHRENE DERIVATIVE; PROTEASOME; THAPSIGARGIN; TRANSMEMBRANE CONDUCTANCE REGULATOR;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CYSTIC FIBROSIS; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MEMBRANE CONDUCTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PURIFICATION; RESPIRATORY EPITHELIUM; STRUCTURE ACTIVITY RELATION;

BINDING SITES; CELL LINE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GLYCINE; HUMANS; MUTATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN TRANSPORT; QUINOLIZINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 41149131817     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.134502     Document Type: Article

References (40)

1. Aridor M and Hannan LA (2000) Traffic jam: a compendium of human diseases that affect intracellular transport processes. Traffic 1:836-851.
2. Aridor M and Hannan LA (2002) Traffic jams II: an update of diseases of intracellular transport. Traffic 3:781-790.
3. Becq F, Mettey Y, Gray MA, Galietta LJ, Dormer RL, Merten M, Metaye T, Chappe V, Marvingt-Mounir C, Zegarra-Moran O, et al. (1999) Development of substituted benzo[c]quinolizinium compounds as novel activators of the cystic fibrosis chloride channel. J Biol Chem 274:27415-27425.
4. Bernier V, Bichet DG, and Bouvier M (2004) Pharmacological chaperone action on G-protein-coupled receptors. Curr Opin Pharmacol 4:528-533.
5. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
6. Burrows JA, Willis LK, and Perlmutter DH (2000) Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: a potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. Proc Natl Acad Sci U S A 97:1796-1801.
7. Canu N, Barbato C, Ciotti MT, Serafino A, Dus L, and Calissano P (2000) Proteasome involvement and accumulation of ubiquitinated proteins in cerebellar granule neurons undergoing apoptosis. J Neurosci 20:589-599.
8. Cheng SH, Gregory RJ, Marshall J, Paul S, Souza DW, White GA, O'Riordan CR, and Smith AE (1990) Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63:827-834.
9. Dalemans W, Barbry P, Champigny G, Jallat S, Dott K, Dreyer D, Crystal RG, Pavirani A, Lecocq JP, and Lazdunski M (1991) Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. Nature 354:526-528.
10. Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE, and Welsh MJ (1992) Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 358:761-764.
11. Dormer RL, Derand R, McNeilly CM, Mettey Y, Bulteau-Pignoux L, Metaye T, Vierfond JM, Gray MA, Galietta LJ, Morris MR, et al. (2001a) Correction of delF508-CFTR activity with benzo(c)quinolizinium compounds through facilitation of its processing in cystic fibrosis airway cells. J Cell Sci 114:4073-4081.
12. Dormer RL, McNeilly CM, Morris MR, Pereira MM, Doull IJ, Becq F, Mettey Y, Vierfond JM, and McPherson MA (2001b) Localisation of wild-type and DeltaF508-CFTR in nasal epithelial cells. Pflugers Arch 443 (Suppl 1):S117-S120.
13. Egan ME, Glockner-Pagel J, Ambrose C, Cahill PA, Pappoe L, Balamuth N, Cho E, Canny S, Wagner CA, Geibel J, et al. (2002) Calcium-pump inhibitors induce functional surface expression of Delta F508-CFTR protein in cystic fibrosis epithelial cells. Nat Med 8:485-492.
14. Egan ME, Pearson M, Weiner SA, Rajendran V, Rubin D, Glockner-Pagel J, Canny S, Du K, Lukacs GL, and Caplan MJ (2004) Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 304:600-602.
15. Ellgaard L and Helenius A (2003) Quality control in the endoplasmic reticulum. Nat Rev Mol Cell Biol 4:181-191.
16. Fuller W and Cuthbert AW (2000) Post-translational disruption of the delta F508 cystic fibrosis transmembrane conductance regulator (CFTR)-molecular chaperone complex with geldanamycin stabilizes delta F508 CFTR in the rabbit reticulocyte lysate. J Biol Chem 275:37462-37468.
17. Gong Q, Jones MA, and Zhou Z (2006) Mechanisms of pharmacological rescue of trafficking-defective hERG mutant channels in human long QT syndrome. J Biol Chem 281:4069-4074.
18. Jefferson DM, Valentich JD, Marini FC, Grubman SA, Iannuzzi MC, Dorkin HL, Li M, Klinger KW, and Welsh MJ (1990) Expression of normal and cystic fibrosis phenotypes by continuous airway epithelial cell lines. Am J Physiol 259:496-505.
19. Jensen TJ, Loo MA, Pind S, Williams DB, Goldberg AL, and Riordan JR (1995) Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell 83:129-135.
20. Jiang C, Fang SL, Xiao YF, O'Connor SP, Nadler SG, Lee DW, Jefferson DM, Kaplan JM, Smith AE, and Cheng SH (1998) Partial restoration of cAMP-stimulated CFTR chloride channel activity in DeltaF508 cells by deoxyspergualin. Am J Physiol Cell Physiol 275:C171-C178.
21. Kartner N, Augustinas O, Jensen TJ, Naismith AL, and Riordan JR (1992) Mislocalization of delta F508 CFTR in cystic fibrosis sweat gland. Nat Genet 1:321-327.
22. Ma T, Thiagarajah JR, Yang H, Sonawane ND, Folli C, Galietta LJ, and Verkman AS (2002) Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. J Clin Invest 110:1651-1658.
23. MacDonald KD, McKenzie KR, and Zeitlin PL (2007) Cystic fibrosis transmembrane regulator protein mutations: "class" opportunity for novel drug innovation. Paediatr Drugs 9:1-10.
24. Marivingt-Mounir C, Norez C, Derand R, Bulteau-Pignoux L, Nguyen-Huy D, Viossat B, Morgant G, Becq F, Vierfond JM, and Mettey Y (2004) Synthesis, SAR, crystal structure, and biological evaluation of benzoquinoliziniums as activators of wild-type and mutant cystic fibrosis transmembrane conductance regulator channels. J Med Chem 47:962-972.
25. Melin P, Thoreau V, Norez C, Bilan F, Kitzis A, and Becq F (2004) The cystic fibrosis mutation G1349D within the signature motif LSHGH of NBD2 abolishes the activation of CFTR chloride channels by genistein. Biochem Pharmacol 67:2187-2196.
26. Meusser B, Hirsch C, Jarosch E, and Sommer T (2005) ERAD: the long road to destruction. Nat Cell Biol 7:766-772.
27. Norez C, Heda GD, Jensen T, Kogan I, Hughes LK, Auzanneau C, Derand R, Bulteaux-Pignoux L, Li C, Ramjeesingh M, et al. (2004) Determination of CFTR chloride channel activity and pharmacology using radiotracer flux methods. J Cyst Fibros 3 (Suppl 2):119-121.
28. 2+ level in the endoplasmic reticulum restores abnormal endogenous F508del-CFTR trafficking in airway epithelial cells. Traffic 7:562-573.
29. Norez C, Noel S, Wilke M, Bijvelds M, Jorna H, Melin P, DeJonge H, and Becq F (2006b) Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the alpha-glucosidase inhibitor miglustat. FEBS Lett 580:2081-2086.
30. Powell K and Zeitlin PL (2002) Therapeutic approaches to repair defects in deltaF508 CFTR folding and cellular targeting. Adv Drug Deliv Rev 54:1395-1408.
31. Robert J, Auzan C, Ventura MA, and Clauser E (2005) Mechanisms of cell-surface rerouting of an endoplasmic reticulum-retained mutant of the vasopressin V1b/V3 receptor by a pharmacological chaperone. J Biol Chem 280:42198-42206.
32. Rubenstein RC, Egan ME, and Zeitlin PL (1997) In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. J Clin Invest 100:2457-2465.
33. Rubenstein RC and Zeitlin PL (2000) Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of DeltaF508-CFTR. Am J Physiol Cell Physiol 278:C259-C267.
34. Stratford FL, Pereira MM, Becq F, McPherson MA, and Dormer RL (2003) Benzo-(c)quinolizinium drugs inhibit degradation of Delta F508-CFTR cytoplasmic domain. Biochem Biophys Res Commun 300:524-530.
35. Ulloa-Aguirre A, Janovick JA, Brothers SP, and Conn PM (2004) Pharmacologic rescue of conformationally-defective proteins: implications for the treatment of human disease. Traffic 5:821-837.
36. Vankeerberghen A, Wei L, Jaspers M, Cassiman JJ, Nilius B, and Cuppens H (1998) Characterization of 19 disease-associated missense mutations in the regulatory domain of the cystic fibrosis transmembrane conductance regulator. Hum Mol Genet 7:1761-1769.
37. Vij N, Fang S, and Zeitlin PL (2006) Selective inhibition of endoplasmic reticulum-associated degradation rescues DeltaF508-cystic fibrosis transmembrane regulator and suppresses interleukin-8 levels: therapeutic implications. J Biol Chem 281:17369-17378.
38. Wang Y, Bartlett MC, Loo TW, and Clarke DM (2006) Specific rescue of cystic fibrosis transmembrane conductance regulator processing mutants using pharmacological chaperones. Mol Pharmacol 70:297-302.
39. Ward CL, Omura S, and Kopito RR (1995) Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 83:121-127.
40. Welsh MJ and Smith AE (1993) Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 73:1251-1254.